ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificate

ZHIFEI-BIOL announced that its wholly-owned subsidiary ZHIFEI-Longke has developed an influenza virus split vaccine that has received the "Drug Registration Certificate" issued by the National Medical Products Administration. This vaccine is suitable for individuals aged 32 and above to prevent infectious diseases caused by influenza virus and is currently one of the main products for influenza prevention both domestically and internationally. The trivalent influenza vaccine that has obtained the drug registration certificate, along with the quadrivalent influenza virus split vaccine that has been approved for market launch, the quadrivalent/trivalent influenza virus split vaccine that is under review for market launch, the quadrivalent influenza virus split vaccine that is in Phase I/II clinical trials, and the trivalent influenza virus split vaccine that has been approved for clinical use, constitutes a comprehensive series of influenza vaccine products covering all age groups and with a rich variety